- Home
- VSTM vs NBP Comparison
VSTM vs NBP Comparison
Compare VSTM & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VSTM | NBP |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | United States |
| Employees | N/A | 32 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 470.7M | 379.3M |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | VSTM | NBP |
|---|---|---|
| Price | $5.62 | $2.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $16.50 | $9.00 |
| AVG Volume (30 Days) | ★ 2.1M | 955.1K |
| Earning Date | 05-12-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.49 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,914,000.00 | N/A |
| Revenue This Year | $282.64 | N/A |
| Revenue Next Year | $72.25 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 209.14 | N/A |
| 52 Week Low | $4.01 | $2.10 |
| 52 Week High | $11.25 | $5.19 |
Technical Indicators
Market Signals| Indicator | VSTM | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 53.26 | 37.48 |
| Support Level | $5.48 | $2.10 |
| Resistance Level | $6.79 | $3.80 |
| Average True Range (ATR) | 0.40 | 0.21 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 91.55 | 44.78 |
Price Performance
Historical ComparisonAbout VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. It integrates scientific discovery with strategic planning and project management to move therapies from research toward potential patient use. Its pipeline includes Givastomig, VIS-101, Ragistomig and Uliledlimab.